Gene therapy (AAV vector) · Gene replacement · developed by Sarepta Therapeutics
rAAVrh74.MHCK7.DYSF.DV is a recombinant adeno-associated virus vector carrying a dysferlin (DYSF) transgene under a muscle-specific MHCK7 promoter. It is designed to deliver the dysferlin gene to muscle and is studied in dysferlinopathy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02710500 | Phase 1 | Dysferlinopathy | Completed | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dysferlinopathy
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →